Help your patients with AS achieve LASTING disease control
Please see clinical trial and primary end points, key data, and study designs
In MEASURE 2,* as observed in a mixed population
At Week 16, 51% of patients achieved ≥1.1 change in ASDAS-CRP on COSENTYX 150 mg (n=67)3
In MEASURE 2, change in ASDAS-CRP ≥1.1 was an exploratory end point in a mixed population. No clinical or statistical conclusions can be drawn.2,3
ASAS-EULAR Guidelines define clinically important improvement as ≥1.1 change in ASDAS-CRP after at least 12 weeks of treatment.1
ASDAS-CRP is a composite index used to assess disease activity using CRP levels, patient global assessment, and BASDAI.3
FAST and LASTING reductions in AS disease activity4
In MEASURE 2, as observed in biologic-naive patients
In MEASURE 2, BASDAI was an uncontrolled exploratory analysis as observed from baseline through Year 5. No clinical or statistical conclusions can be drawn.3,4
In a mixed population, mean BASDAI scores improved at Week 16 by -2.3 (6.6 to 4.3) for COSENTYX 150 mg (n=67) vs -1.0 (6.9 to 5.9) for placebo (n=64). At Year 5, mean BASDAI scores improved by -2.7 (6.5 to 3.8) in the COSENTYX 150-mg group (n=54).4
The analysis of BASDAI in the mixed population at Week 16 was a secondary end point.3
In biologic-naive patients, mean baseline score at Week 16 and Year 5: 6.6.4
Patients with missing data at a specific time point are not included in the analysis. As with other uncontrolled exploratory analyses, this analysis has limitations (eg, no placebo comparisons).4
Definitions
AS, ankylosing spondylitis; ASAS, Assessment of SpondyloArthritis International Society; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score–C-reactive protein; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; EULAR, European Alliance of Associations for Rheumatology; nr-axSpA, non-radiographic axial spondyloarthritis; SC, subcutaneous.
References
1. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19-34.
2. Marzo-Ortega G, Sieper J, Kivitz AJ, et al. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol. 2020;2(6):e339-e346.
3. Data on file. CAIN457F2310 (MEASURE 2): Clinical Study Report. Novartis Pharmaceuticals Corp; November 2014.
4. Data on file. CAIN457F2310 (MEASURE 2): Data Analysis Report. Novartis Pharmaceuticals Corp; June 2019.
5. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.